pillbase.ru

Enhertu

Active substance: trastuzumab deruxtecan

INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION · TRASTUZUMAB DERUXTECAN 100 mg/5mL

United StatesActive

Marketing holder: Daiichi Sankyo Inc.

Verified 2026-10-09 · openFDA NDC

Analogues in other countries
Composition
Analogues by country

Products with the same active substance registered in other countries.

CountryProducts
RU 1
  • ЭНХЕРТУ
    лиофилизат для приготовления концентрата для приготовления раствора для инфузий, 100 мг, 100 мг (original in Russian, GRLS)
    ЛП-№(001242)-(РГ-RU)
    АстраЗенека ЮК Лимитед
EU 1
  • Enhertu
    trastuzumab deruxtecan
    EMEA/H/C/005124
    Daiichi Sankyo Europe GmbH
Import and control

Control by country

  • Russiaprescription only

    Source: GRLS (Russian state register) · record 01a120c3-3d5e-7714-9bb5-12c083ce05bb;count=1 · valid from 2026-10-09 · verified 2026-10-09

  • United Statesprescription only

    Source: openFDA NDC · record 01a12099-1acc-7b07-a302-fdb666a34b33;count=1 · valid from 2026-10-09 · verified 2026-10-09

More on control status
Registration
Registration number
65597-406
Registration status
Active
Dispensing
Prescription only
Route
INTRAVENOUS
Sources
  • product · openFDA NDC · 65597-406 · Verified 2026-10-09 · open in source
  • registration_status · openFDA NDC · 65597-406 · Verified 2026-10-09 · open in source
  • ingredients.0 · openFDA NDC · 65597-406 · Verified 2026-10-09 · open in source